Skip to main content
Equibles
ECOR logo

ECOR · electroCore, Inc. · Metrics

Track ECOR — free

Use ECOR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ECOR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.42 +0.66 (+8.51%) Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company's currently forecasted cash is less than the requirements to fund its operating expenses, future investments and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$69.96M
Shares
9.02M
Volume · Oct 28 45.04K Avg daily vol (3M) 87.69K

ECOR metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.42
Market cap
$69.96M

Price action

20 metrics
Price change (1W)
+3.6%
Price change (30D)
-29.6%
Price change (3M)
+27.4%
Price change (6M)
+26.2%
Price change (YTD)
+73.0%
Price change (1Y)
+58.4%
Trailing year
Price change (5Y)
—
52-week high
$12.29
52-week low
$4.42
Change from 52-week high
-36.9%
Change from 52-week low
+75.6%
Annualized volatility
88.4%
Annualized volatility (3M)
75.5%
Beta
1.9
RSI (14D)
36.7
Price vs SMA 50
-19.5%
Price vs SMA 200
+0.6%
Avg volume (3M)
87,380
Relative volume
0.7
Average dollar volume
$806,577

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
9.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.8×
reciprocal yield 55.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 52.8%
P / book
—
FCF yield
-13.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 57.8%
EV / revenue historical average (5Y)
2.6×
reciprocal yield 38.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
87.1%
Operating margin
-37.6%
Trailing 12 months
Net margin
-40.0%
Gross profit (TTM)
$32.18M
Operating profit (TTM)
−$13.91M
Net income (TTM)
−$14.77M
Trailing 12 months
Diluted EPS (TTM)
$-1.66
FCF margin
-26.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4,145.61
Gross profit per diluted share (TTM)
$3,608.75
Operating profit per diluted share (TTM)
$-1,561.38
EBITDA per diluted share (TTM)
$-1,532.37
Net income per diluted share (TTM)
$-1,659.16
Operating cash flow per diluted share (TTM)
$-1,081.21
Free cash flow per diluted share (TTM)
$-1,082.33
Capital expenditures per diluted share (TTM)
$1.12
R&D per diluted share (TTM)
$351.68
Stock compensation per diluted share (TTM)
$298.09
Book value per share
$-0.21

Growth

11 metrics
Revenue growth YoY
+28.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$36.97M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+13.1%
Year over year · more shares
Revenue CAGR (3Y)
+55.1%
Revenue CAGR (5Y)
+55.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-86.6%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$13.66M
Free cash flow (TTM)
−$9.74M
Quick ratio
1.0
Interest coverage
-1,095.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.28M
Latest balance sheet
Cash & equivalents
$8.50M
Total assets
$17.06M
Total debt
$6.77M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$9.73M
Capital expenditures (TTM)
$10,000
R&D (TTM)
$3.14M
SG&A (TTM)
$42.95M
Stock compensation (TTM)
$2.68M
R&D / revenue
8.5%
Stock compensation / revenue
7.2%

Ownership (13F)

9 metrics
13F filers
33
13F filer change QoQ
+3
Institutional ownership
12.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.8%
Private-fund adviser ownership
5.0%
Active holders' share change QoQ
+50.7%
Holder tenure
7.3
Price vs estimated holder cost
+11.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.2%

Short interest

3 metrics
Short interest
3.9%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$52,763
Insider-sentiment score
53 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1560258 CUSIP 28531P202 13F (30d) 3 filings 3 filers Visit website Investor relations